You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 1
  • P08.09 Genome-wide CRISPR/Cas9 screening for identification of tumor-intrinsic mechanisms of resistance to anti-PD1 therapy in high-risk neuroblastoma

Article info

Article menu

Download PDFPDF

Poster Presentations
P08 Combination therapy
P08.09 Genome-wide CRISPR/Cas9 screening for identification of tumor-intrinsic mechanisms of resistance to anti-PD1 therapy in high-risk neuroblastoma
Free

Authors

Citation

Nagarajan D, Kutkaite G, Tunali G, et al
P08.09 Genome-wide CRISPR/Cas9 screening for identification of tumor-intrinsic mechanisms of resistance to anti-PD1 therapy in high-risk neuroblastoma
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-ITOC9.55

Publication history

  • First published September 21, 2022.
Online issue publication 
September 21, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.